../Morning Post
Posted February11, 2011

____________________
Pharmacology

More advantages found for new drug: McMaster study

Hamilton - New findings from a McMaster University-led study of a drug recently identified to prevent stroke in patients with atrial fibrillation have been published in the high-impact New England Journal of Medicine.

The investigators are now reporting that, in high risk patients who have already had a stroke or warning stroke, apixaban reduces stroke or embolism from 8.3% per year on aspirin to 2.5% per year. This means that one stroke would be prevented, each year, for every 20 of these high risk patients treated with the new drug, apixaban.

The study has found the drug apixaban is superior to aspirin in reducing stroke or embolism in patients with atrial fibrillation who are unsuitable for the traditional therapy of warfarin. It reduces the risk of stroke by more than 50%. Compared to aspirin, apixaban did not significantly increase the risk of major bleeding. Apixaban is a new anticoagulant, still under regulatory review, that blocks the activity of Factor Xa.

“Patients with a stroke who have atrial fibrillation and who cannot take warfarin are at particularly high risk of recurrent stroke,” said principal investigator Dr. Stuart Connolly, a professor of medicine at McMaster University and the Population Health Research Institute of McMaster and Hamilton Health Sciences. “It is great to know that we now have a drug that can reduce recurrent strokes substantially in these patients and which most patients will be able to take without the need for monitoring.”

The full report published on the NEJM website follows preliminary results of the AVERROES study of apixaban presented last year. The report is also being presented today at the American Stroke Association’s international conference in Los Angeles, CA.

Approximately one in four for people aged 40 or older will develop atrial fibrillation, or irregular heart beat, during their lifetime. The biggest threat from AF is a greatly increased risk of stroke, which is five times higher than for others. Blood thinners such as warfarin reduce this risk but are very hard to use successfully. About a third of AF patients are unsuitable for the treatment with warfarin, a vitamin K antagonist, which requires life-long blood monitoring.

Submit press release to pressrelease@exchangemagazine.com - Editor Jon Rohr - Content published on this site represents the opinion of the individual/organization and/or source provider of the Content. ExchangeMagazine.com is non-partisan, online journal. Privacy Policy. Copyright of Exchange produced editorial is the copyright of Exchange Business Communications Inc. 2010/*.*. Additional editorials, comments and releases are copyright of respective source(s) and/or institutions or organizations.

 

Advertisements:
As part of our expansion program, our company is looking for part time work from home account managers and sales representatives. It pays $2000 a month plus benefits and takes only little of your time. Requirements should be a computer literate, 23 hours access to the internet weekly, must be efficient and dedicated. If you are interested and need more information, contact Dan Frank Email:danfrank003@gmail.com
Advertise a text link on the Exchange Morning Post website find out more here


Contact an Exchange Representative

Current Issue November 2010
Receive the Social Media Version of Exchange Online Now












Submit Press Release
Visitor Centre
Weather
Advertising Inquires
Email
Tel: 519.886.0298

Subscribe to Exchange Magazine Print Edition

Contact Information:

Publisher:
Exchange Business Communication Inc.
Waterloo, Ontario, Canada
Tel: 519.886.0298

Editor-in-Chief
Jon Rohr
editor@exchangemagazine.com

Account Manager

John Hobin
john.hobin@exchangemagazine.com